The VIRAGE2 enrollment completion (H2 2026) and initial data (Q3 2027) are the next key catalysts, but the $11.3M cash runway into Q1 2027 creates financing overhang. Monitor for partnership, grant, or equity offering announcements given the 88% analyst bullish consensus but $11M market cap.
Drug in focus
TOVX drug pipeline →VCN-01
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
- Time to market
- Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
- Next catalyst
- None dated
What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $0.2300entry
- T+1 · 3mo ago +4.35%α +4.10% · $0.2400
- T+5 · 3mo ago −1.96%α −1.55% · $0.2255
- T+20 · 2mo ago +8.26%α +9.32% · $0.2490
- T+60 · 13d ago −18.09%α −17.95% · $0.1884
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per share) in Q2 2025, driven by a $9.2M decrease in contingent consideration fair value adjustment. The company dosed first patients in the VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in metastatic PDAC, but cash runway extends only into Q1 2027 with $11.3M on hand, raising financing risk for a clinical-stage company with no revenue.
Key Financial Metrics
Key Facts
- First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment expected to complete H2 2026 with data by Q3 2027
- Cash and cash equivalents of $11.3M as of June 30, 2026; cash runway into Q1 2027
- Net loss of $3.2M for Q2 2026 vs $13.1M in Q2 2025, primarily due to a $9.2M decrease in contingent consideration fair value adjustment
- General and administrative expenses decreased 82% to $2.0M from $11.2M; R&D expenses decreased 35% to $1.3M from $2.0M
- EPS of -$0.07 vs -$1.93 in prior year period, but weighted average shares increased from 6.8M to 45.9M
- Proposed Phase 2/3 trial for VCN-01 in retinoblastoma; FDA discussion planned for Q3 2026
- Phase 1 HNSCC results published in Clinical Cancer Research showing prolonged OS with VCN-01 + durvalumab
Financial Impact
Net loss of $3.2M in Q2 2026 vs $13.1M in Q2 2025; cash burn of $1.7M in H1 2026; $11.3M cash runway into Q1 2027
Risk Factors
- Cash runway only into Q1 2027 with no revenue; likely need to raise capital within 6-9 months
- VIRAGE2 is a small 6-patient proof-of-concept trial; results may not support Phase 3 design
- SYN-004 enrollment paused pending grant/partnership funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342623 |
Track record
11 reports on TOVX
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Viewing Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers